Location History:
- San Diego, CA (US) (1998)
- La Jolla, CA (US) (1997 - 2000)
Company Filing History:
Years Active: 1997-2000
Title: Markley C Leavitt: Innovator in Retroviral Research
Introduction
Markley C Leavitt is a notable inventor based in La Jolla, California. He has made significant contributions to the field of retroviral research, particularly in the development of methods to combat HIV infection. With a total of 4 patents to his name, Leavitt's work has the potential to impact the lives of many individuals affected by this virus.
Latest Patents
Leavitt's latest patents include innovative approaches to using retroviral vectors for therapeutic purposes. One of his key inventions involves retroviral vectors comprising an anti-HIV or other nucleic acid. This invention provides an infectious retrovirus that has a nucleic acid encoding an anti-HIV-type specific agent inserted between the 5' and 3' long terminal repeat sequences of the retrovirus. The nucleic acid is under the control of a pol III promoter, allowing for effective expression. Additionally, he has developed methods for interfering with or preventing HIV viral replication in infected cells. Another significant patent focuses on methods for inhibiting HIV infection by blocking HIV co-receptor RNA expression. This includes the use of ribozymes that cleave HIV co-receptor RNA, targeting co-receptor proteins such as fusin and CKR5.
Career Highlights
Throughout his career, Leavitt has worked with various organizations, including Immusol, Incorporated and the University of California. His research has been pivotal in advancing our understanding of retroviral mechanisms and developing potential treatments for HIV.
Collaborations
Leavitt has collaborated with notable individuals in his field, including Mang Yu and Richard Tritz. These partnerships have contributed to the success of his research and the development of his patents.
Conclusion
Markley C Leavitt's innovative work in retroviral research highlights his commitment to finding solutions for HIV infection. His patents and collaborations reflect a dedication to advancing medical science and improving patient outcomes.